Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country save search
AGENTIX Corporation and the National Health Research Institutions Announce Worldwide Exclusive License Agreements
Published: 2021-09-08 (Crawled : 15:00) - biospace.com/
AGTX | $0.0321 5632.09% 300
|
Manufacturing
| Email alert
Add to watchlist
license research
Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
Published: 2022-04-27 (Crawled : 12:20) - biospace.com/
AMBS | $0.0001 2400.0% 200K
|
Manufacturing
|
| O: 4.17%
H: 36.0%
C: 0.0%
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 0.79%
H: 3.91%
C: 2.34%
corporation potential
Clinical Research Alliance Announces New Partnership With Quality Cancer Care, P.C.
Published: 2023-02-09 (Crawled : 15:00) - biospace.com/
OHCS | $0.08 820.64% 0
|
n/a
| Email alert
Add to watchlist
partnership research cancer
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-18 (Crawled : 16:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
association cancer cell research meeting therapeutics results platform
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
Published: 2022-10-18 (Crawled : 12:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
|
| O: -26.47%
H: 36.0%
C: 36.0%
preclinical therapeutics platform
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
Published: 2022-09-27 (Crawled : 13:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 5.0%
H: 23.33%
C: -1.9%
gdf15 patent biomarker
Q BIOMED PROVIDES SHAREHOLDER UPDATE
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 3.33%
H: 12.9%
C: 6.45%
update
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Published: 2022-07-28 (Crawled : 12:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: -3.36%
H: 4.35%
C: 3.48%
covid biomarker diagnostics
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Published: 2022-06-23 (Crawled : 12:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 2.42%
H: 9.45%
C: 1.57%
tollovid research covid market
Q BioMed Inc. Provides Update to Shareholders
Published: 2022-07-29 (Crawled : 15:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: -9.36%
H: 0.65%
C: -35.61%
update
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 6.0%
H: 27.17%
C: 2.12%
drug research liver cancer
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market
Published: 2022-03-07 (Crawled : 20:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 8.06%
H: 0.0%
C: -13.57%
chinese order 500
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-27 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 12.52%
H: 7.57%
C: -22.72%
covid-19 treatment phase 2 trial covid tollovir antiviral
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 10.0%
H: 7.27%
C: -1.82%
covid-19 treatment phase 2 trial covid tollovir
Q BioMed Inc. Provides Update to Shareholders - June 23, 2023
Published: 2023-06-23 (Crawled : 13:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 3833.33%
H: 0.0%
C: -94.07%
update
Emergent Health To Exhibit at the 30th Annual "A4M Winter World Congress" December 9th - 11th at the Venetian Convention and Expo Center
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
EMGE | $0.0024 94.44% 470K
|
Wholesale Trade
|
| O: 16.0%
H: 0.0%
C: -6.9%
health
Emergent's Director and Chief Marketing Officer Marvin Segel - Son of QVC Founder Joseph Segel - To Appear Live Today on the Emerging Growth Conference at 2:15 PM ET
Published: 2022-08-17 (Crawled : 12:00) - biospace.com/
EMGE | $0.0024 94.44% 470K
|
Wholesale Trade
|
| O: -4.19%
H: 11.87%
C: 5.62%
conference qvc today growth
Emergent Reports Revenues of Approximately $408,000 for the Quarter Ended December 31st, 2022, as Compared to Approximately $185,000 for the Quarter Ended September 30, 2022, an Increase of Over 100%
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
EMGE | $0.0024 94.44% 470K
|
Wholesale Trade
|
| O: 28.13%
H: 2.44%
C: -7.32%
Emergent Intends to Become a Fully Reporting SEC Issuer and List its Shares on the OTCQB
Published: 2023-01-10 (Crawled : 14:00) - biospace.com/
EMGE | $0.0024 94.44% 470K
|
Wholesale Trade
|
| O: 6.25%
H: 17.65%
C: 17.65%
otcqb
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
RILY | $21.72 0.84% 32.09% 1.9M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
WIMI | $0.7254 5.45% 24.7% 4.1M
|
Technology Services
WISA 4 | $5.39 24.77% 23.27% 150K
|
Electronic Technology
TPET | $0.3601 -4.51% 23.11% 11M
|
n/a
VLCN | $0.2946 26.38% 17.69% 390K
|
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
VRT 4 | $79.17 4.08% 15.6% 1.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
Your saved searches
Save your searches and get alerts when important news are released.